Traws Pharma Faces Nasdaq Delisting After Stock Sinks Below $1
TRAW is trading near its 52-week low of $0.43 (4.6% above the low).
Summary
Traws Pharma received a Nasdaq delisting notice on July 29, 2026, after its stock price remained below $1.00 for 30 consecutive business days. The company has until January 25, 2027, to regain compliance or face delisting.
Key Events · Legal and Risk Events · TRAW
-
Nasdaq Delisting Notice Received
On July 29, 2026, Traws Pharma received a deficiency letter from Nasdaq because its common stock closed below $1.00 per share for 30 consecutive business days, violating the minimum bid price requirement.
-
180-Day Compliance Period
The company has until January 25, 2027, to regain compliance by maintaining a closing bid price of at least $1.00 for 10 consecutive business days. A second 180-day grace period may be available if certain conditions are met.
-
Delisting Risk
If compliance is not regained within the allotted period(s), Nasdaq will initiate delisting proceedings, though the company can appeal. There is no assurance of regaining compliance.
-
Financial Distress Context
The delisting notice follows a Q1 2026 report of zero revenue, a $7.1 million net loss, and a going concern warning. The stock is trading near its 52-week low of $0.43, and a planned Phase 2a influenza study was recently deferred.
Analysis · TRAW · Life Sciences
Nasdaq has notified Traws Pharma that its stock price has fallen below the $1.00 minimum bid requirement for 30 consecutive business days, triggering a delisting warning. The company now has 180 days, until January 25, 2027, to regain compliance by trading at or above $1.00 for at least 10 consecutive business days. This development arrives amid a severe financial crisis: zero revenue, a going concern warning, and a stock trading near its 52-week low of $0.43. The delisting notice adds immediate pressure to execute a reverse stock split or other corrective action, as failure to regain compliance would force the stock off the Nasdaq Capital Market, severely limiting liquidity and institutional access. Further complicating the path to recovery are the company's recent history of dilutive financings and a deferred clinical trial.
At the time of this filing, TRAW was trading at $0.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $6.9M. The 52-week trading range was $0.43 to $3.27. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.